{"id":"W4295807681","doi":"10.1016/j.jaad.2022.08.061","title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":279,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; LEO Pharma; Eli Lilly and Company; Bristol-Myers Squibb; Galderma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Biogen; Celgene; Amgen; Pfizer","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Adverse effect; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Gastroenterology; Dermatology Life Quality Index; Clinical trial; Dermatology; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782767,0.002056721,0.004459292,0.0004802034,0.0005119274,0.001356071,0.001027581,0.001692892,0.006258347],"category_scores_gemma":[0.001407578,0.0008076032,0.002263139,0.0003633153,0.0009640051,0.001543901,0.0003586113,0.00352447,0.001263109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007755351,"about_ca_system_score_gemma":0.0008891844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007871022,"about_ca_topic_score_gemma":0.002184342,"domain_scores_codex":[0.9993679,0.0002978631,0.00003794902,0.0001251357,0.00005301925,0.0001181634],"domain_scores_gemma":[0.9991711,0.0002144747,0.0001991047,0.00007605607,0.00004971788,0.0002895479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970781,0.004450599,0.0002669129,0.0004714329,0.000877436,0.00002840354,0.00003744714,0.0004046533,0.004032112,0.00007612744,0.00092921,0.01764465],"study_design_scores_gemma":[0.9453799,0.05048682,0.001908543,0.00002322229,0.0003891255,0.00005449025,0.00002447109,0.0005111312,0.0005957703,0.0001275438,0.0004762069,0.00002281163],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871132,0.006336355,0.000644265,0.0006501307,0.0004249802,0.001260793,0.001158728,0.0002824939,0.00212905],"genre_scores_gemma":[0.9894887,0.002775171,0.0008599355,0.0007020523,0.0003600364,0.001240061,0.001070542,0.00005278691,0.003450793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006258347,"threshold_uncertainty_score":0.02093625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05161720070112816,"score_gpt":0.3402775865708558,"score_spread":0.2886603858697276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}